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ORIGINAL ARTICLE
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1Department of Surgery, 2Department of Nutrition, 3Department of Preventive Medicine, 4Department of Metabolomics and Proteomics
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Abstract
Background: The incidence of liver disease is increasing in USA. Animal models had shown glutathione
species in plasma reflects liver glutathione state and it could be a surrogate for the detection of hepa-
tocellular carcinoma (HCC).
Methods: The present study aimed to translate methods to the human and to explore the role of
glutathione/metabolic prints in the progression of liver dysfunction and in the detection of HCC. Treated
plasma from healthy subjects (n = 20), patients with liver disease (ESLD, n = 99) and patients after
transplantation (LTx, n = 7) were analyzed by GC- or LC/MS. Glutathione labeling profile was measured
by isotopomer analyzes of 2H2O enriched plasma. Principal Component Analyzes (PCA) were used to
determined metabolic prints.
Results: There was a significant difference in glutathione/metabolic profiles from patients with ESLD vs
healthy subjects and patients after LTx. Similar significant differences were noted on patients with
ESLD when stratified by the MELD score. PCA analyses showed myristic acid, citric acid, succinic acid,
L-methionine, D-threitol, fumaric acid, pipecolic acid, isoleucine, hydroxy-butyrate and glycolic, steraric
and hexanoic acids were discriminative metabolites for ESLD-HCC+ vs ESLD-HCC− subject status.
Conclusions: Glutathione species and metabolic prints defined liver disease severity and may serve as
surrogate for the detection of HCC in patients with established cirrhosis.
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Introduction
The incidence of end stage liver disease (ESLD) has increased in
the last decade in the USA due mainly to a high incidence of
HCV infection and an epidemic of obesity; the main risk factor
for non-alcoholic steatohepatitis (NASH).1,2 It is estimated that
4 million of Americans are infected with HCV and 1 out of 3
adults are overweight.3,4 Non-invasive markers for liver disease
progression are not well defined as they are the factors that
predict the transformation from a compensated state of
cirrhosis to a decompensated one.5–7 Furthermore, reliable
biomarkers for early detection of hepatocellular carcinoma
(HCC) in this high risk population are in need.8
Genetic prints on malignant tissue from patients with ESLD
have shown diverse gene patterns likely due, at least in part to the
heterogeneity in the mechanisms of liver injury and the variety of
This work was presented in part at the ASTS Philadelphia 2011,
AHPBA/IHPBA Buenos Aires 2012 and AHPBA/IHPBA Sao Paulo 2016.
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pathways for hepatocyte malignant transformation.9–13 In
addition, there is no standardization in the method used to take
and process tissue samples from tumor biopsies, or from tumor
explants after surgery at different ischemic times during the
operation. The integration of gene alterations to specific protein
disturbances and metabolic patterns could provide a better un-
derstanding of the patient in whom disarrangements in liver
physiology, portal blood flow, and malignant transformation
occur at once.14–18 Our group has shown a linear correlation of
glutathione species concentration in plasma with glutathione
species concentration from liver tissue.19 Furthermore, an
animal model with normal livers but tumor implants had shown
disturbances of the glutathione species and changes on metabolic
prints when compared to controls; changes in the glutathione
species were also noted in an animal model with cirrhosis and
HCC.20–22 The present study aims to translate methods from the
animal model to the human, to determine changes in glutathione
species and in the metabolic patterns of patients with progressive
liver disease, and to determine differences in patients with ESLD
with and without HCC. The present studies showed Glutathione
species and metabolic prints defined liver disease severity and
may serve as surrogate for the detection of HCC in patients with
established cirrhosis.
Material and methods
Population
Three sets of subjects were enrolled on IRB approved protocols:
healthy subjects (n = 20), patients with end stage liver disease
(ESLD) and diverse liver injury (stratified by the MELD score,
n = 99), and patients >30 days after liver transplantation (LTx)
with normal graft function (n = 7). All subjects were approached
during their visit to liver clinics, and protocols were presented
and explained. Consented patients were scheduled for a second
visit where clinical variables were captured, and blood and urine
samples were obtained and processed. A subset of patients
(healthy controls, n = 10; patients with diverse MELD score, n = 7
and patients after liver transplantation, n = 7) were enrolled for
the labeling studies as described below. All studies were con-
ducted according with the guidelines at Case Western Reserve
University andWestern IRB (Copernicus Group) under approved
protocols at University Hospitals Case Medical Center (Cleve-
land) and Cancer Treatment Centers of America (Chicago).
The general dual protocol was aimed at i) measuring both the
concentration and turnover of GSH-GSSG, and ophthalmate
(from treated plasma and from 2H-enriched body water,
respectively), and ii) evaluating the metabolome of the subjects
over two Tiers of metabolites. In Tier 1, the concentration of
glutathione species and 3 metabolites were measured (glucose,
glycerol and lactate), while in Tier 2, the concentration of 78
metabolites were identified, respectively. An initial exploratory
run of 21 metabolites was performed in healthy controls under
fasted and fed conditions. To further assess liver physiology in
healthy subjects without the need of getting a liver biopsy, pre-
albumin and IGF-1 concentrations were measured by standard
ELISA techniques (Sigma–Aldrich, St. Louis MO). All samples
from patients with ESLD were taken in the fasted state in the
morning hours under no sleep deprived conditions.23,24
For the labeling studies, subjects were investigated at the
Clinical Research Center (CWRU, Cleveland) and it involved: i)
overnight fasting of the subject/patient, ii) insertion of a venous
blood sampling catheter in a wrist vein, iii) collection of baseline
blood and urine samples, iv) ingestion of glass-distilled 99%
2H2O (Sigma Aldrich, San Louis MO) in amount that enriched
body water at 0.5% (250 ml/75 kg, ingested slowly over 1 h (the
beginning of 2H2O ingestion sets the time at 0 h), v) blood
sampling every hour from 1 to 8 h after starting 2H2O ingestion.
Subjects/patients were asked to remain recumbent from 0 to
3 h to avoid vertigo or nausea and to assure better water distri-
bution. Enrolled healthy subjects were asked for a second visit
where the 2H2O was provided after the ingestion of a stan-
dardized 800 calorie meal.
Blood and urine sampling processing
Five mL of blood was withdrawn from patients using a vacu-
tainer system and collected in a heparinized solution to be placed
in a centrifuge at a temperature of 4 C for 10 min. Plasma was
carefully separated from RBC’s and both aliquots were treated as
described below; they were saved & labeled at −70 C until mass
spectrometry processing. 5–10 ml of urine were collected in pre-
labeled sterile containers and saved at −70 C. Urine samples
were used in the identification of spectra peaks on unknown
origin suspected to be from medications.
Dot connecting test
At the end of each study visit, every participant across the various
study groups did a Dot-connecting test to assess grade of en-
cephalopathy. The Dot connecting test consists of drawing a line
connecting numbered dots already present on a sheet of paper,
going from 1 to 15. The amount of time the subject spends
performing the dot connecting test was recorded. It was
administered in a set of six different formats (A–G) and the
results were averaged and expressed in seconds.
Glutathione sp. concentration
Materials and reagents
General chemicals, as well as 2H2O (99%, glass distilled) and
[13C2,
15N-glycine]glutathione (M3 GSH) were from Sigma–
Aldrich (St. Louis, MO). Homoglutathione was from Chem-
Impex International (Wood Dale, IL). Ophthalmic acid was
from Bachem (Torrance, CA). Acetonitrile was procured from
Fisher Scientific (Pittsburgh, PA).
Glutathione species
Plasma concentration of glutathione species GSH:GSSG and OA
were measured using LC-MS/MS methods validated in our
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laboratory.21 In brief, the protected plasma samples were spiked
with homoglutathione as an internal standard. Iodoacetate
treated samples were kept in the dark at room temperature for
45 min to allow completion of the reaction. To liberate the bound
glutathione, 200 ml of DTT (100 mM, pH 10, in 10 mM
ammonium bicarbonate) was added and allowed to react in the
dark for 15 min at room temperature. To this solution, 200 ml of
iodoacetonitrile [200 mM, pH 10, in 10 mM ammonium bicar-
bonate containing 3.12 mM homoglutathione (623 pmol/200 ml)]
was added to convert the liberated glutathione to a cyanomethyl-
thioether. After 30 min standing at room temperature in the dark,
1.5 ml of acetonitrile was added to precipitate the proteins. After
completing all reactions, the sample was dried at 50 C under air
at 20 psi for 40 min and reconstituted in formic acid in water
(0.1% vol:vol). This sample was injected into a liquid chro-
matograph (Agilent 1100, Agilent Technologies Inc., Palo Alto,
CA) equipped with an API 4000 QTrap mass spectrometer
(Applied Biosystems, Foster City, CA) operated under positive
ionization mode. A Hypersil Gold C18 column (2.1 × 150 mm,
5 mm particle size; Thermo Electron Corp.) was used at room
temperature. Mobile phase A was 0.15% formic acid in water-
acetonitrile (99:1, vol:vol), and mobile phase B was 0.15%
formic acid in water-acetonitrile (5:95 vol:vol). Using a gradient
elution, the compounds were eluted at a flow rate of 0.2 ml/min.
Analyst software (version 1.4.1; Applied Biosystems, Foster City,
CA) was used for data registration and analysis. The MRM ion
pairs monitored (precursor:product) were i) for carboxymethyl-
GSH: 366.1:237.2, ii) for cyanomethyl-GSH derived from GSS-
bound: 347.2:272.1, iii) for carboxymethyl-homoglutathione:
380.1:233.1, iv) for cyanomethyl-homoglutathione: 361.1:232.1,
and v) for ophthalmate: 290.3:161.1. The GSH/GSSG-bound
ratio was calculated using the formula [GSH]/[GSSG-bound2].
Concentrations were adjusted accordingly to internal controls.
Metabolic prints
Gas Chromatography-Mass Spectrometry (GC–MS) analyses
were performed on an Agilent 6890 gas chromatograph inter-
faced to an Agilent 5973 mass spectrometer equipped with a
Phenomenex ZB-5 MSi capillary column (30 m × 0.25 mmi.d.,
0.25 mm film thicknesses). Injection volume was 1 mL in split less
mode. Injector temperature was set at 250 C and the transfer
line at 275 C. The carrier gas was helium at a constant flow rate
of 1 mL/min. The GC oven temperature was initially kept at
60 C for 1 min and increased at a rate of 10 C/min to a final
temperature of 325 C held for 10 min. EI ion source tempera-
ture was set to 250 C and the MS quadrupole temperature to
150 C. Mass spectra were acquired in scan mode with a mass
range of 45–800 m/z. The raw data was de-convoluted with the
National Institute of Standards and Technology (NIST) Auto-
mated Mass Spectral Deconvolution and Identification Software
(AMDIS). After spectral analysis and data processing of 113
signals, 78 signals could be identified in 80% of all samples.
Identified signals were confirmed by the Case Core metabolomic
library and the Fiehn library (Agilent Technologies Inc, Santa
Clara, CA). For further quantification, the data was exported to
the SpectConnect server (Massachusetts Institute of Technology,
Cambridge, MA). The concentration of each metabolite was
expressed as its relative peak area (divided by the area of the
corresponding internal standard in the same chromatogram). All
identified metabolic compounds in Tiers 1and 2 (3 and 78 me-
tabolites, respectively) were further used for statistical analyses.
For healthy controls, metabolic compound were measured and
processed at T0 when compared to other groups and at T4 when
healthy controls were compared between fasted and fed states.
Glutathione species labeling profile
When body water is 2H-enriched by ingestion of 2H2O, amino-
acids become labeled by exchange reactions with the H of water.
Once incorporated into proteins or peptides, the labeling of the
aminoacids is stable. The measurement of the 2H-enrichment of
proteins or peptides allows the calculation of their fractional rate
of production. Since GSH is a peptide, its rate of synthesis in
various organs can be accessed from the incorporation of 2H
from 2H-enriched body water. Our laboratory had developed
LC-MS/MS assays for the concentration and 2H-enrichment of
GSH and GSSG. To prevent the oxidation of GSH, we immedi-
ately reacted the sample with iodoacetate or iodoacetonitrile to
form the carboxymethyl-GS or cyanomethyl- GS thioether,
respectively. These derivatives yield good MS–MS spectra.
However, GSSG, which does not require protection, yields a very
weak MS signal. To assay reliably GSH and GSSG under similar
conditions, (i) we protect GSH with iodoacetate, then (ii) we
reduce GSSG with dithiothreitol and protect the newly formed
GSH with iodoacetonitrile. This one-pot preparation allows us to
assay extant GSH and GSH derived from GSSG in the same LC-
MS/MS run. Homo-GSH (glutamate-cysteine-alanine) is used
twice as an internal standard as previously described.19
Treatment of samples and LC–MS/MS
The treatment of samples and the process to obtain the spectra
were carried out as described previously.19 Analyst software
(version 1.4.2; Applied Biosystems) was used for data registra-
tion. Mass spectra were acquired under three modes. First, the
enhanced resolution mass spectra of the intact molecules was
recorded. Second, multiple reaction monitoring (MRM) ion
pairs were monitored to acquire data used to calculate isotopic
enrichments from precursor 3-product pairs. The ion pairs
monitored were i) for carboxymethyl-GSH: 366.1 / 237.1,
367.2/ 237.1, and 367.1/ 238.1; ii) for cyanomethyl-GSH
derived from GSSR: 347.2/ 218.1, 348.2/ 218.1, and 348.2
/ 219.1; iii) for carboxymethylhomoglutathione: 380.1 /
233.1; iv) for cyanomethyl-homoglutathione: 361.1 / 232.1;
and v) for ophthalmate: 290.3 / 161.1, 291.3 / 161.1, and
291.3/ 162.1. Third, product ion spectra (MS/MS) were used
to calculate the enrichments of fragments of the carboxymethyl-
GSH derivative; from the precursor ions at mass-to charge ratio
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(m/z) 366.1 and 367.1, we monitor m/z 134 [cysteine (CYS) at
collision energy 33], 237 [glycinyl (GLY)-CYS at collision energy
19], and 291 [glutamyl (GLU)-CYS at collision energy 21], with a
mass width of 5 amu, from m/z 100 to 400. The 2H enrichment
of plasma water was assayed by exchange with unlabeled acetone
in alkaline medium, followed by extraction and GC–MS of
deuterated acetone.
Calculations
The M1
2H enrichment of GSH derivatives was calculated from
MRM data on the basis of the fragmentation patterns of the M
and M1 parent ions of each derivative. The calculations for the
carboxymethyl-GSH derivatives are based on the transitions of
the M parent ion (366.1 / 236.1) and M1 parent ion
(367.1/ 237.1 and 238.1). The M fraction is calculated from
the average peak intensity of the 366.1/ 237.1 MRM pair. The
M1 fraction is calculated as the sum of the average peak in-
tensities of the two MRM pairs 367.1 / 237.1 and
367.1/ 238.1. The mole percent enrichment of the GSH de-
rivative is calculated as M1/(M + M1). The contribution of M2
and higher mass isotopomers to the calculation is inconse-
quential. In experiments where M3 GSH was used, we measured
the abundances of the M–M3 species. For the M2 isotopomer, we
calculated the sum of the average peak intensities of three MRM
pairs (368.1/ 237.1, 238.1, and 239.1). For the M3 isotopomer,
we calculated the sum of average peak intensities of four MRM
pairs (369.1 / 237.1, 238.1, 239.1, and 240.1). The M3 mole
percent enrichment of the GSH derivative was calculated as M3/
(M + M1 + M2 + M3. The above calculations use the average
intensities of the peaks at retention time ±0.1 min. Data were
processed using a Visual Basic script,1 which simplifies peak
integration by opening the files sequentially, and then trans-
ferring the average intensity of the selected peaks to an Excel
spreadsheet.
The M1 enrichment of the constitutive amino acids of GSH
was calculated from the product ion spectra of the derivatives.
Calculations used data from the most abundant product ions:m/
z 134 (CYS), 237 (GLY-CYS), and 291 (GLU-CYS), monitored
with a mass width of 5 amu. The enrichment of GLY was
calculated from the difference in enrichment of GLY-CYS and
CYS. The enrichment of GLU was calculated from the difference
in enrichment of GLU-CYS and CYS. We fit the time course
labeling data to a model for a single compartment using
nonlinear regression implemented with the Origin statistical
package (OriginLab, Northampton, MA). We used the Box-
Lucas 1 model, which fits the data to the equation E(t) = Einf
Table 1 Demographic variables of normal subjects, patients with different degrees of liver disease graded by MELD score and subjects after
liver transplantation
Group Healthy ESLD Post-LTx p-Value*
MELD < 14 MELD ‡ 14
Subjects (n) 20 79 20 7
Gender (M:F) 11:9 43:36 15:5 4:3
Age (years M ± STDV) 33.1 ± 8.7 55.9 ± 11.7 54.5 ± 15.1 55.4 ± 11.0 <0.05
MELD (M ± STDV) 4.8 ± 1.5 8.9 ± 2.5 19.9 ± 6.2 5.7 ± 2.9 <0.05
Creatinine 0.9 ± 0.04 0.97 ± 0.3 1.97 ± 1.2 1.6 ± 0.2
Bilirubin Total 0.5 ± 0.2 1.12 ± 0.9 6.5 ± 11.2 1.1 ± 0.1
INR 0.99 ± 0.0 1.13 ± 0.14 1.44 ± 0.5 1.1 ± 0.4
Child-Pugh Score 5 ± 0 6.26 ± 1.3 8.7 ± 1.8 6.0 ± 1.7 <0.05
Ascites no controlled 0 38 (48%) 15 (75%) 8 (28%)
Encephalopathy (seconds) 11.6 ± 5.3 14.8 ± 7.7 19.6 ± 11.6 19.4 ± 15.3
HCC (yes:no) 0:20 (0%) 13:66 (16%) 3:18 (15%) 0:7 (0%)
Milan criteria NA 8 3 NA
Size NA 3.9 ± 1.7 2.5 ± 1.1 NA
Liver Disease 0 79 20 7a
Conge/metabolic (NASH) NA 16 3 2
Toxic/drug (alcohol) NA 13 6 1
Infectious (HBV/HCV) NA 41 10 3
Cholestatic NA 5 0 0
Other NA 4 1 1
*p < 0.05 by t-test when compared to healthy controls.
a Etiology of liver disease prior LTx.
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(1 − e−kt), where t is time and E(t) is the enrichment of the
isotopomer at time t and Einf is the plateau enrichment. This
equation describes the labeling of the pool with the tracer. The
parameters to be estimated are the plateau enrichment and k,
which is equal to flux/(pool size). We used the calculated 95%
confidence intervals for the parameters as the criteria for
determining difference when comparing the plots.
Statistical approach
Variables were entered in an Excel spreadsheet to be transferred
to JMP statistical software (SAS Institute, Chicago V12). On
continuous numerical non metabolic variables, probability of
difference among groups was performed by ANOVA and be-
tween groups by a two-tailed t-test at a 0.05 level. Metabolites
concentration data were normalized using log transformation.
Difference between groups on categorical variables were tested by
chi-square methods. Metabolic prints among groups were eval-
uated by principal component analyses as described below.
Univariate analyses, t-test, and fold change analysis were
performed to provide a preliminary overview about metabolites
discriminating the groups. For the fold change analysis, a vari-
able was considered as significant if the number was above the
given threshold.
Principal component analyses
Multivariate analysis including Principal Component Analysis
(PCA) and Partial Least Square Discriminant Analysis (PLS-DA)
were conducted to investigate and visualize the pattern of
metabolite differences among groups. PCA is an unsupervised
method aiming to find the directions that best explain the
variance in a data set. PLS-DA model used Variable Importance
in the Projection (VIP) scores to identify the most influential
1
2
3
4
5
GSH GSSG Ratio OA
Control FAST Control FEED
*p<0.05 t-test, n=10
*
*
1
2
3
4
Glucose Glycerol Lactate
Control FAST Control FEED
*p<0.05 t-test, n=10
*
*
*
a b
Figure 1 a. Glutathione species (GSH = glutathione reduced; GSSG = glutathione oxidized and bound; ratio = GSH/GSSG-bound2;
OA = ophthalmic acid)) in healthy controls (n = 10) fasted for 8 h or after subjects were fed an 800 calories meal. Results are expressed as mean
on relative concentration units. There was a statistical significant difference between the fast vs fed status in the relative concentrations of GSH
and OA (t-test, p < 0.05). b. Tier 1 metabolites (glucose, glycerol and lactate) in healthy controls (n = 10) fasted for 8 h or after subjects were fed
standardized 800 calories meal. There was a statistical significant difference between the fast status vs fed in the relative concentrations of
glucose, glycerol and lactate (ANOVA followed by t-test, p < 0.05)
Figure 2 Turn over of glutathione species. (GSH = reduced, GSSG = oxidized and bound and OA = ophthalmate) in healthy subjects (n = 10) by
isotopomer analyses (M1) on 2H2O enriched plasma. There was not a difference in the synthesis of glutathione sp. on healthy subjects a) Fasted
for 8 h vs b) Fed a standardized 800 calorie meal (p > 0.05 by ANOVA)
HPB 2016, 18, 979–990 © 2016 The Authors. Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
HPB 983
metabolites. VIP scores higher than 0.8 are considered as
meaningful. Metabolites with VIP score  1 were considered as
significant important features to differentiate groups. Statistical
analyses were performed using code developed in R (R Devel-
opmental Core Team http://www.R-project.org) and Metab-
oAnalyst 3.0 (Xia, J., Sinelnikov, I., Han, B., and Wishart, D.S.
(2015) MetaboAnalyst 3.0 – making metabolomics more
meaningful. Nucl. Acids Res. (http://dx.doi.org/10.1093/nar/
gkv380).
Results
Main demographic variables of healthy subjects, patients with
ESLD and patients after LTx are showed in Table 1. Healthy
controls were significantly younger and with a lower MELD and
Child Pugh Scores when compared with other groups of patients
(p < 0.05). Patients with ESLD were divided into two subgroups
according to their MELD score. Patients with ESLD either in the
lower/higher MELD score group had similar proportion of HCC
and similar distribution regarding the etiology for their liver
disease.
Healthy subjects
Twenty healthy subjects were included in the present studies; 11
males and 9 females with a mean age of 33.1 ± 8.7 years, and
normal liver function test (not showed). Ten enrolled patients
underwent labeling studies under fasted conditions and after a
standardized 800 calorie meal. Healthy subjects showed higher
concentration of GSH and a lower concentration of OA in the
fasted state compared to the fed state (Fig. 1a, p < 0.05).
Nevertheless, the turnover of GSH was similar (Fig. 2).
Furthermore, healthy subjects differed significantly in the con-
centration of glucose, glycerol and lactate from the fasted state
when compared to the fed state, as expected (Fig. 1b, p < 0.05).
There were no significant differences in the glutathione species
or Tier 1 metabolites when distributed by gender (male vs
female, results no shown). In addition, there was not a statistical
difference in the rate of labeling of GSH or OA between the fasted
vs the feed state in the healthy subjects (Fig. 2). The results of
their metabolic print on 21 compounds under fasted vs fed
conditions are displayed on Table 2. The standardized 800 calorie
meal was high in carbohydrates and proteins, and low in fats. The
findings were consistent with our predictions.
Patients with end stage liver disease (ESLD)
Glutathione species were significantly different in patients with
ESLD when compared to healthy controls (Fig. 3a, p < 0.05).
There was a decreased in the concentration of the reduced
glutathione with change in the GSH/GSSG ratio. In addition, a
significant difference in the Tier 1 metabolic print with marked
decrease in glucose and glycerol and elevated concentration of
lactated in patient with liver disease when compared to healthy
subjects (Fig. 3b, p < 0.05). Alterations in all main metabolites
(amino acids, carbohydrates and lipids) were also observed in
patients with ESLD when compared with controls and those
disturbances were more pronounced in patients with higher
MELD score (>14). PCA showed pyro-glutamic acid, pyruvate,
Table 2 Demographics and metabolite profile on 21 compounds of
normal subjects. Subjects were fast for 8hr prior to the study vs fed a
standardized 800calo meal just prior to the study. All studies were
performed in the morning under no sleep deprivation and under
standardized environment. Relative metabolomic data are
expressed as ratios to an internal standard
Healthy Controls p-Value*
FAST FED
Gender (M:F) 5:5 5:5
Age (years) 44 ± 11 44 ± 11
Race
Caucasian 6 6
African American 2 2
Latino 1 1
Body mass index 25 ± 4 25 ± 4
Pre-albumin (g/dL) 25 ± 8 23 ± 7
IGF-1 122 ± 47 123 ± 52
Co-morbidity HTN (n = 1) HTN (n = 1)
Metabolite
Amino acids
Alanine 0.26 ± 0.21 0.12 ± 0.04 <0.05
Glycine 0.15 ± 0.12 0.17 ± 0.07
Isoleucine 0.05 ± 0.03 0.09 ± 0.03
Lysine 0.18 ± 0.016 0.12 ± 0.22
Proline 0.15 ± 0.16 0.07 ± 0.04 <0.05
Serine 0.08 ± 0.06 0.07 ± 0.03
Valine 0.23 ± 0.28 0.16 ± 0.06
Threonine 0.16 ± 0.12 0.13 ± 0.05
Carbohydrate
Glucose 1.5 ± 1.7 3.47 ± 1.43 <0.05
Fructose 0.02 ± 0.03 0.01 ± 0.01
Pyruvate 0.01 ± 0.00 0.01 ± 0.00
Lactate 1.23 ± 1.10 0.78 ± 0.33
a-Hydroxy-butyrate 0.05 ± 0.06 0.03 ± 0.01
Amino-malonic acid 0.02 ± 0.02 0.01 ± 0.01
Pyroglutamic acid 0.13 ± 0.02 0.11 ± 0.06
Threonic acid 0.01 ± 0.00 0.02 ± 0.00
Lipids
Cholesterol 1.62 ± 0.83 2.44 ± 1.34
Glycerol 0.09 ± 0.04 0.16 ± 0.08
Oleic acid 0.50 ± 0.64 0.56 ± 0.51
Palmitate 1.22 ± 1.06 0.98 ± 0.39
Stearic acid 1.07 ± 0.76 1.12 ± 0.44
*p < 0.05 by t-test.
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cholesterol, glycerol and glucose are significantly different in
patients with ESLD when compared to healthy subjects. In
addition, PLS-DA showed that lysine and fructose may also
discriminate patients with ESLD from healthy subjects (Fig. 4).
Patients with ESLD by etiology
A trend for some differences was observed in the glutathione
species when patients with ESLD were grouped by their etiology
of liver disease (Table 3). OA was noted to be significantly
increased in patient with infectious causes (HCV/HBV). PCA
and PLA-DA were not performed due to the low numbers of
patients in some of the etiology groups.
Patients with ESLD and hepatocellular carcinoma
(HCC)
Patients with ESLD with and without malignancy showed a
significant difference on their glutathione species profile when
compared to controls (Fig. 5a, p < 0.05). Tier 1 metabolic print
differed significantly in patients with ESLD by tumor status,
ESLD & HCC− vs ESLC & HCC+ (Fig. 5b, p < 0.05). Tier 2
1
2
3
4
5
Healthy Control ESLD MELD<14 ESLD MELD>=14
GSSGGSH OARatio
*p<0.05 ANOVA
*
*
*
0.5
1
1.5
2
2.5
Healthy Control ESLD MELD<14 ESLD MELD>=14
GlycerolGlucose Lactate
*p<0.05 ANOVA
*
*
*
a b
Figure 3 a. Glutathione species (GSH = glutathione reduced; GSSG = glutathione oxidized and bound; ratio = GSH/GSSG-bound2;
OA = ophthalmic acid)) in fasted subjects from healthy controls (n = 20) and patients with end stage liver disease stratified by the MELD score
(<14; n = 72) and 14; n = 27). Results are expressed as mean on relative concentration units. There was a statistical significant difference
between the glutathione species print from patients with ESLD (either lower or higher MELD scores) compared to the print of healthy individuals
(p < 0.05, by t-test). In addition there was a significant difference in the glutathione species print of patients with ESLD and lower vs higher MELD
score (p < 0.05). b. Tier 1 metabolites (glucose, glycerol and lactate) in fasted subjects from healthy controls (n = 20) and form patients with end
stage liver disease stratified by the MELD score (<14; n = 72) and 14; n = 27). There was a statistical significant difference between the Tier 1
metabolic print from patients with ESLD (either lower or higher MELD scores) compared to the print of healthy individuals (p < 0.05). In addition
there was a significant difference in the Tier 1 metabolic print of patients with ESLD and lower vs higher MELD score (p < 0.05, by t-test)
Figure 4 Principal Component Analyses (PCA) and Volcano Plot of metabolites in patients with ESLD. a. Tier 2 metabolites were measured in
patients with end stage liver disease (ESLD) and healthy subjects. In was found pyro-glutamic acid, pyruvate, cholesterol and glucose signif-
icantly discriminate patients with ESLD and MELD 14 when compared to healthy controls. Results are displayed in b as a Volcano plot. In
addition, PLS-DA, found lysine and fructose as additional discriminant metabolites between compared groups (VP scores no shown)
HPB 2016, 18, 979–990 © 2016 The Authors. Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
HPB 985
metabolites were measured in patients with ESLD and tumor vs
healthy subjects. In was found, by PCA and PLS-DA cholesterol,
pyroglutamic acid, inositol, ethanolamine, fructose, pyruvate,
citric acid and lysine were discriminative metabolites. Additional
metabolites displayed in the volcano plot included glycolic acid,
galacturonic acid and ribose (Fig. 6). Tier 2 metabolites were
measured in patients with ESLD-HCC+ vs ESLD-HCC−. PCA
and PLS-da analyses showed myristic acid, citric acid, succinic
acid, L-methionine, D-threitol, fumaric acid, pipecolic acid,
isoleucine, glycolic acid, hydroy-butyrate, steraric acid and
hexanoic acid were discriminative metabolites (Fig. 6). No
additional metabolites were found in the volcano plot.
Glutathione species labeling in patients with ESLD
and after LTx
Patients with ESLD has a significant decreased in the labeling of
GSH and an increased labeling of GSSG-bound when compared
to healthy controls and patients after liver transplantation
(p < 0.05). Patients after LTx has a similar profile as healthy
controls (Fig. 7).
Discussion
The incidence of liver disease is increasing in the USA.1,3,4 ESLD
is the most significant risk factor for the development of HCC,
malignancy that has tripled its incidence in USA during the last
decade.2,25 Nevertheless, the detection of this malignancy on
high risks population still relies on imaging modalities with up to
80% of cases being found at an advanced stage. The present study
is aimed to determine metabolic prints and changes in the
glutathione redox system in plasma from patients with ESLD. It
was observed a significant different profile on patients with ESLD
when stratified by MELD score when compared to the healthy
subjects. Patients with ESLD had a significantly different
Table 3 Glutathione species of healthy subjects and patients with ESLD stratified by disease process categories: metabolic (NASH), toxic
(alcohol related), infectious (HCV, HBV), cholestatic (autoimmune, PSC, PBC) and other (SBC, chronic rejection)
Healthy ESLD p-Value*
Metab Toxic Infec Choles Other
Subjects (n) 20 5 4 35 2 8
MELD 4.3 ± 1.2 14 ± 5.3 17 ± 27.5 11.7 ± 4.8 11 ± 2.8 10.1 ± 2.3 <0.05
Child-Pugh 5.0 ± 0.0 7.6 ± 2.3 8.5 ± 2.4 6.8 ± 1.5 6 ± 0 5.6 ± 0.7 <0.05
Encephalopathy (seconds) 12.3 ± 5.2 13.8 ± 3.7 9.6 ± 2.7 16.7 ± 8.2 20.5 ± 12 29.2 ± 23 <0.05
GSH (nMol/ml) 3.9 ± 1.6 2.5 ± 1.3 2.4 ± 1.2 3.5 ± 4.8 2.8 ± 0.5 2.6 ± 1.4
GSSG-bound 3.6 ± 1.4 1.9 ± 1.0 1.8 ± 0.9 2.6 ± 2.8 1.5 ± 0.4 2.0 ± 0.8 <0.05
OA 4.0 ± 4 6.4 ± 4.7 5.9 ± 3.1 8.9 ± 4.6 5.7 ± 4.4 4.9 ± 4.5 <0.05
*p < 0.05 by t-test when compared to healthy controls.
1
2
3
4
5
Healthy Control ESLD HCC(-) ESLD HCC (+)
GSSGGSH OARatio
*p<0.05 ANOVA
*
*
0.5
1
1.5
2
2.5
Healthy Control ESLD HCC (-) ESLD HCC (+)
GlycerolGlucose Lactate
*p<0.05 ANOVA
*
*
*
a b
Figure 5 a. Glutathione species (GSH = glutathione reduced; GSSG = glutathione oxidized and bound; ratio = GSH/GSSG-bound2;
OA = ophthalmic acid)) in fasted subjects from three groups: healthy controls (n = 20), patients with end stage liver disease and no primary
malignancy (HCC−, n = 83) and patients with end stage liver disease and primary malignancy (HCC+, n = 16). Results are expressed as mean on
relative concentration units. There was a statistical significant difference between the glutathione species from patients with ESLD with or
without malignancy compared to the print of healthy individuals (p < 0.05, by ANOVA followed by t-test). b. Tier 1 metabolites (glucose, glycerol
and lactate) in fasted subjects from healthy controls (n = 20) and patients with ESLD by tumor status. There was a statistical significant difference
between the Tier 1 metabolic print from patients with ESLD with or without malignancy compared to the print of healthy individuals (p < 0.05).
Furthermore, there was a significant difference in the Tier 1 metabolic print of patients with ESLD and HCC− vs HCC+ (p < 0.05)
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glutathione species print and metabolic profile according to their
tumor status. Patients with ESLD had a significantly different
turn-over of glutathione species when compared to healthy
subjects and to patients after liver transplantation.
We hypothesized that glutathione species print was a sensitive
tool to detect oxidative stress of liver cells but not specific to the
etiology of the injury. Nevertheless, the mechanism of the injury,
as it differs according to the agent, may have a different metabolic
print. Therefore, the measurement of glutathione species and the
metabolic print of an individual may provide us with the severity
of the insult and a metabolic print specific to the injury and to
the state of liver disease and its progression. Patients with
worsening liver dysfunction may have a different metabolic
profile than a patient with progressive portal hypertension and
both prints may add to the predictive value of the profile. In
addition, the development of malignancy could not only
aggravate the metabolic stress but also add a new profile. The
present study showed that it is possible to i) differentiate patients
with ESLD from healthy subjects based on the liver stress and
their metabolic print, ii) to grade patients into low and high
MELD scores (liver dysfunction), and iii) it may be possible to
categorize subjects with ESLD by their tumor status. In addition,
we may be able to follow the progress of patients by the etiology
of their liver injury. Perhaps and instead of focusing on each
metabolic path that may be altered in the individual or in the
overall group, we would like to focus in ways that further define
metabolic patterns of liver dysfunction and progression to ESLD
and malignancy. Nonetheless, specific metabolic paths may serve
as therapeutic targets or markers of response/failure to an
intervention.
It was found that glutathione species and metabolic prints
differentiated patients with low and high MELD score from
Figure 6 Volcano Plot of metabolites by PCA & PLS-DA in patients with ESLD. a. Tier 2 metabolites were measured in patients with end stage
liver disease (ESLD) and tumor (n = 16)) vs healthy subjects (n = 20). In was found cholesterol, pyroglutamic acid, inositol, ethanolamine,
fructose, pyruvate, citric acid and lysine were discriminative metabolites. Additional metabolites displayed in the volcano plot included glycolic
acid, galacturonic acid and ribose. Importance in projection (VIP) Scores for each metabolite found by PLS-DA are displayed. b. Tier 2 me-
tabolites were measured in patients with ESLD-HCC+ (n = 16)) vs ESLD-HCC−(n = 68). It was found myristic acid, citric acid, succinic acid, L-
methionine, D-threitol, fumaric acid, pipecolic acid, isoleucine, glycolic acid, hydroy-butirate, steraric acid and hexanoic acid were discriminative
metabolites. No additional metabolites were found in the volcano plot. Importance in projection (VIP) Scores for each metabolite found by PLS-
DA are displayed
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healthy subjects. The MELD score predicts 90 days survival of
patients with ESLD in the waiting list for LTx and predict post-
operative complications after surgery of patients with liver dis-
ease.26–30 PCA and PLS-DA provided metabolic prints of
patients with ESLD distributed by high or low MED scores. Thus
changes in the glutathione species and metabolic patterns can
measure progression of liver dysfunction, it could detect changes
from a state of ESLD compensated to uncompensated one and
perhaps predict survival of the patients in the LTx waiting list or
graft function after transplantation. Furthermore, the metabolic
changes noted during liver injury by a specific process, i.e.
NASH, HCV had prints of common metabolites changes and
prints of specific metabolites disturbances according to its eti-
ology. The specific metabolic signature for an individual patient
could be determined according to his/her etiology and disease
progression. Early detection of a path for decompensation in a
given etiology or for malignant transformation could alert the
clinician for a timely intervention.31,32 The number of patients
required to validate such predictions are much larger and a
matter of future studies.
Another aim of the present study was to translate methods
from animal models where it was found glutathione species and
metabolic disturbances were present in the early development of
tumor cells; not only in normal livers but in livers with advanced
fibrosis. Glutathione species and metabolic prints discriminate
patients with ESLD and HCC from healthy patients, and more
importantly they may discriminate subjects with tumors from
patients with ESLD and no malignancy. Metabolic prints may
prove to be a method for screening populations at high risk of
developing HCC.33 The present study was not designed to
correlate histology or tumor staging with a specific metabolic
printing.34 Nevertheless, it would be a focus of another study to
determine the metabolic print of primary liver tumors and their
stage vs secondary tumors. In addition, we would like to deter-
mine if the grade of tumor differentiation could provide a spe-
cific metabolic printing that would predict and correlate with
patient survival.18,33
Glutathione species alterations were found to be a sensitive
marker of liver stress imposed by any injury to the parenchymal
cells and manifested in plasma on their reduced or oxidized
forms. In addition, OA was noted to have similar sensitivity but
also misses the specificity of the injury. The nature of the
glutathione alterations was not approached in the present study
neither their association with any specific etiology. Nevertheless,
the labeling of glutathione reduced was significantly decreased
while the labeling of glutathione oxidized was increased in pa-
tients with ESLD when compared to healthy subjects and to
patients after liver transplantation with normal graft function.
The higher disturbances were noted in patients with HCC and in
patients with active viral infections. Even though the labeling of
glutathione reduced was normalized after liver transplantation,
the ratio of the reduced/oxidized glutathione forms and the
concentration OA were increased in these patients when
compared to healthy controls. This occurred even though they
had normal graft function, perhaps reflecting an ongoing liver
stress not obvious by routine liver tests.
The present studies should be taken in the light of some
limitations. Standardization of procedures and MS techniques in
a timely fashion are required if metabolic profiles are to be
adopted for clinical use in the future. In addition, the further
development of metabolic libraries will help to define and
correlate specific metabolic prints with the specific state of liver
dysfunction, portal hypertension, and tumor status for the in-
dividual. Since glutathione species and metabolic profiles are
performed in processed plasma, it may prove to be a useful
method for screening high risk populations for disease pro-
gression and perhaps by tumor status. Nonetheless, the number
of patients presented in the present study are relatively low and
values and profiles may vary as more studies are performed.
In conclusion, the present study has shown that glutathione
species alterations and metabolic prints measured in plasma
from patients with ESLD discriminated patients from healthy
subjects, graded patients by the severity of their liver condition,
and may categorize patients by the presence or absence of HCC.
Figure 7 Synthesis of glutathione sp. (GSH = reduced and GSSG = oxidized and bound) in fasted subjects from three groups: a) healthy controls
(n = 10), b) patients with end stage liver disease (ESLD, n = 7) and c) patients after liver transplantation (LTx, n = 7). There was a statistical
significant difference between the glutathione species labeling from patients with ESLD when compared to the glutathione synthesis from
healthy individuals (p < 0.05 by ANOVA). The glutathione labeling from patients after liver transplantation were similar to the one from healthy
patients
HPB 2016, 18, 979–990 © 2016 The Authors. Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
988 HPB
Further studies are needed to define the role of glutathione
species and metabolic prints and their correlations with clinical
variables to determine their predictive value and function as a
screening tool.
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